1 Department of Radiology, Columbia University Medical Center, New York, NY.
2 Department of Medical Imaging, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
AJR Am J Roentgenol. 2017 Jul;209(1):205-213. doi: 10.2214/AJR.16.17713. Epub 2017 May 15.
The purpose of this study was to identify the details of percutaneous catheter drainage (PCD) of pyogenic liver abscesses, the etiologic factors, and the management techniques that contribute to successful treatment.
The records of 75 consecutively registered patients who underwent PCD of 96 abscesses at a single institution between May 2009 and May 2014 were retrospectively reviewed. Thirty-nine patients (52%) were oncology patients, and 36 (48%) had recently undergone abdominal surgery. Primary success was defined as abscess healing with the primary PCD intervention and 30-day postdrainage survival. Salvage success was defined as abscess healing with follow-up secondary PCD placement for symptomatic hepatic satellite collections or for clinical recurrence. Catheter adjustments were performed during follow-up to optimize existing drains. Univariate, multivariate, and general linear mixed model analyses were performed. The median follow-up time after catheter removal was 6 months (range, 2-62 months).
Drains were primarily successful in 54 patients (72%), and 17 patients (23%) needed salvage PCD; thus, overall success was achieved in 71 patients (95%). The other four patients (5%) died of sepsis. The primary success rate was reduced in patients with unresectable malignancies (p = 0.01), multiple abscesses (p = 0.01), and output ≥ 15 mL/d at catheter endpoint (n = 7, p = 0.001). Only unresectable malignancies had slightly lower overall success. Large abscesses (> 150 cm) required more catheter adjustments and longer drainage duration to reach abscess cavity closure. Successfully drained abscesses reached cavity closure a mean of 23 days (95% CI, 20-27 days) after treatment.
PCD was effective first-line treatment of complicated pyogenic liver abscesses, which often require catheter adjustment and salvage drainage procedures to reliably achieve success.
本研究旨在确定经皮经肝胆道引流术(PCD)治疗化脓性肝脓肿的细节、病因因素和治疗技术,以提高治疗成功率。
回顾性分析 2009 年 5 月至 2014 年 5 月期间在一家机构接受 PCD 治疗的 96 个脓肿的 75 例连续登记患者的记录。39 例(52%)为肿瘤患者,36 例(48%)近期接受过腹部手术。主要成功定义为首次 PCD 干预后脓肿愈合和 30 天引流后存活。挽救性成功定义为通过后续的 PCD 放置治疗症状性肝卫星脓肿或临床复发来治愈脓肿。在随访期间进行导管调整以优化现有引流。进行单变量、多变量和广义线性混合模型分析。导管移除后中位随访时间为 6 个月(范围,2-62 个月)。
54 例(72%)患者的引流初次成功,17 例(23%)需要挽救性 PCD;因此,71 例(95%)患者总体成功。另外 4 例(5%)患者因败血症死亡。不可切除的恶性肿瘤(p = 0.01)、多发性脓肿(p = 0.01)和导管终点时输出量≥15 mL/d 的患者(n = 7,p = 0.001)的初次成功率降低。只有不可切除的恶性肿瘤对整体成功率略有影响。较大的脓肿(>150 cm)需要更多的导管调整和更长的引流时间才能达到脓肿腔闭合。成功引流的脓肿在治疗后平均 23 天(95%CI,20-27 天)达到腔闭合。
PCD 是治疗复杂化脓性肝脓肿的有效一线治疗方法,通常需要进行导管调整和挽救性引流程序以可靠地获得成功。